 |
Prospector
Profile
07.1245
|
| |
| Hemobiotech, Inc. |
NAICS |
541710 |
| 5001 Spring Valley Road, Suite 1040 West
Dallas, TX 75244 |
Description |
Biotechnology |
| (972) 455-8950 |
Employees |
5 |
| http://www.hemobiotech.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-2.5710 |
| |
Assets |
(mil) |
4.2590 |
| |
Liability |
(mil) |
0.1710 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Hemobiotech, Inc. reported a net loss of $882,000 for the three months ended June 30, 2007, compared to a net loss of $555,000 during the same quarter a year ago. For the first half of 2007, the Company reported a net loss of $1,710,000, a 55% increase over the net loss of $1,102,000 during the first half of 2006. As a result of its recurring losses, the Company has an accumulated deficit of $9,846,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company has licensed from Texas Tech University Health Service Center exclusive worldwide rights for HemoTech under a U.S. patent issued in August 1995. The patent, U.S. Patent No. 5,439,882, entitled "Blood Substitute," and its foreign counterparts, claim various alternative compositions of the novel blood substitute based on hemoglobin of both bovine and human origin as well as methods for its production and use. Protection under this U.S. patent expires on August 8, 2012. The Compny's licensed foreign patents have been issued by or designated in 21 foreign nations. Furthermore, continued testing of HemoTech may result in refinements that are patentable, thereby extending patent protection for forthcoming HemoTech derivatives. [SEC Filing 10-KSB 03-27-07]
|
| |
|
Description:
The Company engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Science Center School of Medicine.
|
| |
|
Officers:
Arthur P. Bollon, Ph.D. (Chair, Pres. & CEO); Mark J. Rosenblum, C.P.A. (CFO & Sec.); Jan Simoni, Ph.D., D.V.M. (VP); Mario Feola, M.D. (Chief Medical Officer)
|
| |
|
Auditor:
Eisner LLP
|
| |
|
Securities:
Common Stock-Symbol HMBT.OB; OTC BB;
18,436,887 common shares outstanding as of August 3, 2007.
|
| |
| |
| |
| return to main page |
|
|
